Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisinopril
Drug ID BADD_D01300
Description Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs.[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384]
Indications and Usage Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]
Marketing Status approved; investigational
ATC Code C09AA03
DrugBank ID DB00722
KEGG ID D00362; D08131
MeSH ID D017706
PubChem ID 5362119
TTD Drug ID D07HGR
NDC Product Code 64220-154; 65862-037; 16571-797; 16571-798; 42708-031; 42708-033; 43353-270; 43353-271; 43547-417; 50090-2228; 50090-4678; 51655-707; 53002-1225; 55154-2128; 60687-325; 60760-359; 61919-246; 62135-641; 63187-099; 63629-8823; 65862-039; 65862-040; 65862-042; 68001-336; 68071-5143; 68084-196; 68645-551; 68645-587; 68645-613; 70518-0117; 70518-2600; 71335-0176; 71335-1380; 71610-612; 0615-8254; 76282-419; 76282-729; 0591-0405; 0591-0409; 0904-6797; 0904-7200; 57297-511; 63827-1012; 16729-376; 16729-379; 43353-113; 43353-993; 43547-351; 43547-355; 50090-3763; 51655-146; 55154-8096; 55289-884; 60687-333; 61919-746; 62135-642; 63187-237; 63187-442; 65862-038; 68001-334; 68071-3220; 68180-982; 68645-608; 68645-610; 68788-6407; 70518-1790; 70518-1906; 0591-0406; 71335-0354; 71610-588; 0615-8253; 72865-208; 72865-209; 76282-422; 76282-731; 76282-733; 82009-063; 65862-041; 65977-0009; 23155-714; 31722-172; 42708-142; 43353-301; 50090-3765; 50090-3774; 50090-4725; 50090-4885; 50436-0352; 50436-0354; 51655-399; 51655-729; 51655-999; 58118-1980; 60687-678; 60760-380; 62135-644; 63187-775; 63629-5247; 67296-1202; 67296-1839; 68180-517; 68180-981; 68645-550; 68645-555; 69117-0037; 70882-104; 71205-471; 71335-1295; 71610-624; 0615-8255; 61919-909; 62135-645; 63187-257; 63187-821; 63629-8736; 68001-335; 68180-513; 68645-593; 68788-7012; 68788-7334; 69117-0036; 70518-0544; 70882-103; 70934-155; 71205-180; 71205-742; 71335-0015; 71610-638; 0615-8405; 72865-210; 82009-065; 82982-066; 14593-944; 17404-0011; 16571-794; 16571-795; 42708-154; 43547-418; 43547-419; 50090-0808; 52427-441; 58118-1981; 60760-360; 61919-721; 62135-643; 63187-534; 63629-1761; 67296-1452; 68001-337; 68071-3123; 68645-552; 68645-553; 68645-609; 68788-6820; 68788-6920; 69117-0038; 69117-1003; 70518-1152; 70882-110; 70934-338; 70934-522; 70934-919; 71205-071; 76282-728; 76282-730; 82009-066; 0591-0885; 16571-796; 16729-377; 43063-480; 43063-810; 43063-812; 43547-353; 51655-486; 52427-438; 53002-1123; 60687-646; 60687-667; 63187-825; 68001-332; 68001-486; 68071-3409; 68071-5190; 68180-512; 68180-979; 68180-980; 68645-554; 68645-611; 68788-8351; 70518-0468; 70934-171; 71205-626; 0615-8252; 0904-6800; 67651-0225; 31722-179; 31722-180; 42708-176; 43063-769; 43547-352; 43547-354; 43547-356; 50090-2989; 50090-3175; 51655-995; 52652-3001; 53002-1178; 53002-1463; 60760-358; 60760-390; 60760-438; 61919-717; 61919-736; 63187-098; 63187-780; 68001-333; 68071-2224; 68071-3411; 68084-765; 70518-2561; 70518-2655; 0591-0407; 72789-093; 72789-101; 72865-211; 76282-420; 76282-421; 82009-064; 64220-142; 16729-380; 23155-710; 23155-711; 23155-712; 43063-786; 43063-800; 43063-811; 43063-813; 43353-297; 43353-643; 43353-662; 43353-793; 43547-415; 50090-6303; 51655-335; 51655-411; 52427-442; 62135-640; 63187-722; 68071-3064; 68788-8310; 69117-1001; 71335-0075; 71610-312; 71610-406; 71610-536; 72865-212; 76282-418; 0904-6798; 0904-6799; 65730-1301; 42708-096; 42708-165; 50090-2431; 50090-4887; 52427-443; 55154-4992; 55154-8078; 55700-480; 60760-357; 60760-455; 68645-532; 70518-1156; 70518-1316; 70518-3166; 0591-0408; 76282-417; 16571-799; 16729-375; 31722-176; 31722-178; 42708-032; 43063-074; 43353-009; 43353-298; 43547-414; 43547-416; 50090-5120; 50436-0353; 51655-994; 52427-440; 53002-2123; 55154-2329; 55700-479; 55700-547; 60687-656; 67296-1154; 68645-612; 68788-7666; 69117-1002; 71335-0498; 71335-0536; 72865-213; 76282-732; 82009-062; 16729-378; 23155-713; 23155-715; 31722-177; 42708-094; 43063-814; 43063-815; 52427-439
UNII E7199S1YWR
Synonyms Lisinopril | Lysinopril | Lisinopril Sulfate (1:2) | Prinivil | Zestril | Lisinopril Maleate (1:1) | MK-521
Chemical Information
Molecular Formula C21H31N3O5
CAS Registry Number 76547-98-3
SMILES C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Palatal swelling07.05.04.0090.000005%Not Available
Nodular rash23.03.13.0210.000027%Not Available
End stage renal disease20.01.03.0190.000018%Not Available
Tongue discomfort07.14.02.0190.000010%Not Available
Allergic reaction to excipient10.01.01.0350.000015%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.038--Not Available
Glomerulonephritis acute20.05.01.0200.000005%Not Available
Immune-mediated myositis15.05.01.012; 10.02.01.0880.000007%Not Available
No reaction on previous exposure to drug08.06.01.0420.000012%Not Available
Pharyngeal swelling22.04.05.0280.000071%Not Available
Post streptococcal glomerulonephritis20.05.01.023; 11.07.01.0290.000005%Not Available
Reaction to azo-dyes10.01.01.0400.000010%Not Available
Reaction to excipient10.01.01.0420.000023%Not Available
Similar reaction on previous exposure to drug08.06.01.0460.000005%Not Available
Sprue-like enteropathy14.02.01.011; 07.17.01.0140.000020%Not Available
Symptom recurrence08.01.03.1010.000015%Not Available
Therapeutic response changed08.06.01.0590.000005%Not Available
Uvulitis07.05.01.0230.000005%Not Available
The 17th Page    First    Pre   17    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene